Skip to main content

Table 2 Anthropometric, metabolic and cardiovascular parameters at baseline and post interventions

From: Reduction in peripheral vascular resistance predicts improvement in insulin clearance following weight loss

Variables

Control

HCD

Group × time interaction (P)

Baseline

Week 16

Baseline

Week 16

Anthropometric

 Body weight (kg)

97.8 ± 4.0

98.2 ± 4.2

98.6 ± 4.1

90.4 ± 4.0***

<0.001

 Δ

 

0.4 ± 0.4

 

−8.1 ± 0.6‡

 

 Body mass index (kg/m2)

32.8 ± 0.9

32.9 ± 1.0

33.9 ± 1.7

31.2 ± 1.7***

<0.001

 Δ

 

0.2 ± 0.2

 

−2.7 ± 0.2‡

 

 Waist circumference (cm)

106.1 ± 2.3

106.5 ± 2.2

107.8 ± 2.8

100.3 ± 2.8***

<0.001

 Δ

 

0.4 ± 0.4

 

−7.5 ± 0.9‡

 

 Waist to hip ratio

0.91 ± 0.02

0.92 ± 0.02

0.91 ± 0.02

0.89 ± 0.01***

0.001

 Δ

 

0.0 ± 0.0

 

−0.03 ± 0.01‡

 

 Total body fat mass (kg)

38.0 ± 2.9

38.0 ± 3.0

42.0 ± 2.7

35.8 ± 3.1***

<0.001

 Δ

 

0.1 ± 0.3

 

−6.2 ± 0.7‡

 

Metabolic and biochemical

 Fasting glucose (mmol/L)

5.8 ± 0.1

5.9 ± 0.1

6.1 ± 0.2

5.8 ± 0.1**

0.03

 Δ

 

0.0 ± 0.1

 

−0.3 ± 0.1†

 

 Fasting insulin (mU/L)

18.8 ± 1.7

20.4 ± 1.6*

18.0 ± 1.4

13.8 ± 1.2***‡

<0.001

 Δ

 

1.7 ± 0.9

 

−4.2 ± 0.7‡

 

 Triglycerides (mmol/L)

1.5 ± 0.1

1.4 ± 0.1

1.7 ± 0.2

1.1 ± 0.1***

0.02

 Δ

 

−0.1 ± 0.1

 

−0.6 ± 0.2†

 

 HDL-cholesterol (mmol/L)

1.29 ± 0.07

1.20 ± 0.06*

1.21 ± 0.05

1.25 ± 0.07

0.02

 Δ

 

−0.09 ± 0.04

 

0.04 ± 0.03†

 

 LDL-cholesterol (mmol/L)

3.4 ± 0.1

3.4 ± 0.2

3.8 ± 0.2

3.5 ± 0.2**

0.02

 Δ

 

0.0 ± 0.1

 

−0.3 ± 0.1†

 

 NEFA (mEq/L)

0.53 ± 0.04

0.51 ± 0.04

0.57 ± 0.05

0.55 ± 0.04

0.93

 Δ

 

−0.02 ± 0.03

 

−0.02 ± 0.04

 

 Leptin (ng/mL)

18.7 ± 4.6

19.1 ± 3.6

21.6 ± 4.7

13.1 ± 3.4***

<0.001

 Δ

 

0.4 ± 1.6

 

−8.5 ± 2.1‡

 

 High sensitivity CRP (mg/L)

3.3 ± 0.8

3.5 ± 0.9

3.2 ± 0.6

2.2 ± 0.4*

0.12

 Δ

 

0.2 ± 0.6

 

−0.9 ± 0.3†

 

 Creatinine clearance (mL/min)

150 ± 11

147 ± 9

140 ± 10

118 ± 7**†

0.06

 Δ

 

−3 ± 6

 

−22 ± 10

 

Cardiovascular

 Clinic MAP (mmHg)

92 ± 3

95 ± 3

89 ± 2

86 ± 2*

0.007

 Δ

 

3 ± 2

 

−3 ± 1‡

 

 Clinic heart rate (bpm)

62 ± 2

61 ± 2

62 ± 2

59 ± 2*

0.41

 Δ

 

−2 ± 1

 

−3 ± 1

 

 Cardiac BRS (ms/mmHg)

15.7 ± 2.2

15.7 ± 1.9

18.0 ± 2.6

23.7 ± 2.9*†

0.16

 Δ

 

0.0 ± 2.2

 

5.8 ± 2.3

 

 Calf vascular resistance (units)

53.0 ± 6.7

57.4 ± 4.4

51.3 ± 4.9

47.1 ± 3.3

0.18

 Δ

 

4.4 ± 4.6

 

−4.2 ± 3.9

 

 Finger reactive hyperaemic index

2.35 ± 0.15

2.42 ± 0.16

2.38 ± 0.19

2.26 ± 0.15

0.44

 Δ

 

0.07 ± 0.13

 

−0.12 ± 0.20

 

 PAT ratio

0.68 ± 0.09

0.67 ± 0.09

0.67 ± 0.10

0.62 ± 0.09

0.77

 Δ

 

−0.01 ± 0.10

 

−0.05 ± 0.11

 

 Cardiac output (L/min)

5.3 ± 0.3

5.6 ± 0.4

5.5 ± 0.4

5.4 ± 0.4

0.30

 Δ

 

0.3 ± 0.2

 

−0.1 ± 0.2

 
  1. BRS baroreflex sensitivity, CRP C-reactive protein, MAP mean arterial pressure, NEFA non-esterified fatty acids, PAT peripheral arterial tonometry
  2. * P < 0.05, ** P < 0.01 and *** P < 0.001 versus Baseline; †P < 0.05 and ‡P ≤ 0.01 versus Control Group